Foamix Pharmaceuticals, Ltd.
2 Holzman Street
Weizmann-Science Park
Rehovot
76704
Tel: 972-8-9316233
Website: http://www.foamix.co.il/
115 articles about Foamix Pharmaceuticals, Ltd.
-
Foamix Pharma Announces Dosing Of First Patient In Phase III Rosacea Clinical Trials For FMX103 Minocycline Foam 1.5%
6/12/2017
-
Foamix Pharma Reports First Quarter 2017 Financial Results And Provides Business Update
5/10/2017
-
Foamix Pharma Announces Plans For Additional Phase III Trial For FMX101 In Moderate To Severe Acne
5/2/2017
-
Foamix Pharma First Quarter Financial Results Conference Call & Webcast Scheduled For Tuesday, May 10
4/26/2017
-
Foamix Pharma Craters As Acne Drug Flunks Phase III Test
3/27/2017
-
Foamix Pharma Reports Year End 2016 Financial Results And Provides Business Update
2/22/2017
-
Foamix Pharma To Release Fiscal Year 2016 Financial Results And Host Conference Call & Webcast On Wednesday, February 22
2/8/2017
-
Foamix Pharma Announces Completion Of Patient Enrollment In Phase 3 Acne Trials For Minocycline Foam FMX101
11/28/2016
-
Foamix Pharma Reports Third Quarter 2016 Financial Results and Provides Business Update
11/16/2016
-
Foamix Pharma Announces Proposed Follow-On Offering Of Ordinary Shares
9/28/2016
-
Foamix Pharma Announces Pricing Of Its $57 Million Follow-On Offering Of Ordinary Shares
9/28/2016
-
Foamix Pharma Announces Positive Topline Results From Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam For Moderate-To-Severe Papulopustular Rosacea
9/12/2016
-
Foamix Pharma To Announce Topline Results In Phase 2 Clinical Trial Of FMX-103 Minocycline Topical Foam For Moderate-To-Severe Papulopustular Rosacea
9/9/2016
-
Foamix Pharma Reports Second Quarter 2016 Financial Results And Provides Business Update
8/10/2016
-
Foamix Pharma Announces Completion Of Enrollment In Phase II Clinical Trial Of Minocycline Foam (FMX103) For Treatment Of Papulopustular Rosacea
5/3/2016
-
Shares Jump as Foamix Pharma's FDX104 Shows Efficacy in Phase II Study
12/3/2015
-
Foamix Pharmaceuticals, Ltd. To Host Conference Call & Webcast To Discuss Topline Results From Phase II Study Of FDX-104 In Acneiform Rash Associated With Targeted Antibody Treatments For Colon And Head And Neck Cancers
12/3/2015
-
Foamix Pharmaceuticals, Ltd. To Present Corporate Overview At The Oppenheimer 26th Annual Healthcare Conference
12/1/2015
-
Foamix Pharmaceuticals, Ltd. To Present Corporate Overview At Jefferies Autumn 2015 Global Healthcare Conference In London
11/11/2015
-
Foamix Pharmaceuticals, Ltd. Reports Third Quarter 2015 Financial Results And Provides Business Update
11/11/2015